VEGFR1/2/3 drugs for Renal Cell Carcinoma

2 tracked VEGFR1/2/3 drugs in the Renal Cell Carcinoma race. The class explanation lives on the VEGFR1/2/3 page; the full indication pipeline across every mechanism is on the Renal Cell Carcinoma page.

1 approved / phase 41 Phase 3

Head-to-head evidence: Axitinib vs Fruquintinib

The roster

← all VEGFR1/2/3 drugs